Nfat	I
and	O
miR-25	I
cooperate	O
to	O
reactivate	O
the	O
transcription	I
factor	I
Hand2	I
in	O
heart	I
failure	I
.	O

Although	O
aberrant	O
reactivation	O
of	O
embryonic	O
gene	I
programs	O
is	O
intricately	O
linked	O
to	O
pathological	I
heart	I
disease	I
,	O
the	O
transcription	I
factors	I
driving	O
these	O
gene	I
programs	O
remain	O
ill-defined	O
.	O

Here	O
we	O
report	O
that	O
increased	O
calcineurin	I
/	O
Nfat	I
signalling	I
and	O
decreased	O
miR-25	I
expression	I
integrate	O
to	O
re-express	O
the	O
basic	I
helix-loop-helix	I
(	O
bHLH	I
)	O
transcription	I
factor	I
dHAND	I
(	O
also	O
known	O
as	O
Hand2	I
)	O
in	O
the	O
diseased	I
human	O
and	O
mouse	O
myocardium	I
.	O

In	O
line	O
,	O
mutant	O
mice	O
overexpressing	O
Hand2	I
in	O
otherwise	O
healthy	I
heart	I
muscle	I
cells	I
developed	O
a	O
phenotype	I
of	O
pathological	I
hypertrophy	I
.	O

Conversely	O
,	O
conditional	O
gene-targeted	I
Hand2	I
mice	O
demonstrated	O
a	O
marked	O
resistance	O
to	O
pressure-overload-induced	I
hypertrophy	I
,	O
fibrosis	I
,	O
ventricular	I
dysfunction	I
and	O
induction	O
of	O
a	O
fetal	O
gene	I
program	O
.	O

Furthermore	O
,	O
in	I
vivo	I
inhibition	O
of	O
miR-25	I
by	O
a	O
specific	O
antagomir	I
evoked	O
spontaneous	O
cardiac	I
dysfunction	I
and	O
sensitized	O
the	O
murine	I
myocardium	I
to	O
heart	I
failure	I
in	O
a	O
Hand2-dependent	I
manner	O
.	O

Our	O
results	O
reveal	O
that	O
signalling	O
cascades	O
integrate	O
with	O
microRNAs	I
to	O
induce	O
the	O
expression	I
of	O
the	O
bHLH	I
transcription	I
factor	I
Hand2	I
in	O
the	O
postnatal	O
mammalian	O
myocardium	I
with	O
impact	O
on	O
embryonic	O
gene	I
programs	O
in	O
heart	I
failure	I
.	O

Heart	I
failure	I
in	O
patients	I
treated	O
with	O
bisphosphonates	I
.	O

OBJECTIVES	O
:	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
occurrence	O
of	O
heart	I
failure	I
in	O
patients	I
treated	O
with	O
bisphosphonates	I
.	O

DESIGN	O
:	O

In	O
this	O
nationwide	O
retrospective	I
cohort	I
study	I
from	O
Denmark	O
,	O
all	O
users	O
of	O
bisphosphonates	I
and	O
raloxifene	I
between	O
1996	O
and	O
2006	O
(	O
n	O
=	O
102	O
342	O
)	O
were	O
included	O
in	O
the	O
'	O
exposed	O
'	O
group	O
and	O
three	O
age	O
-	O
and	O
gender-matched	O
subjects	O
(	O
n	O
=	O
307.026	O
)	O
from	O
the	O
general	O
population	O
comprised	O
the	O
control	O
group	O
.	O

The	O
risk	O
of	O
heart	I
failure	I
was	O
estimated	O
by	O
Cox	I
proportional	I
hazard	I
analyses	I
.	O

RESULTS	O
:	O

The	O
mean	O
follow-up	I
times	O
were	O
2.8	O
,	O
5.5	O
and	O
4.9	O
years	O
for	O
alendronate-	I
,	O
etidronate	I
-	O
and	O
raloxifene-treated	I
patients	I
,	O
respectively	O
.	O

The	O
absolute	O
risk	O
of	O
heart	I
failure	I
was	O
4.4	O
%	O
in	O
the	O
exposed	O
group	O
and	O
3.7	O
%	O
in	O
the	O
control	O
group	O
(	O
P	I
<	O
0.01	O
)	O
.	O

The	O
relative	I
risk	I
(	O
RR	I
)	O
of	O
heart	I
failure	I
was	O
significantly	I
increased	O
in	O
users	O
of	O
bisphophonates	I
:	O
crude	O
RR	I
1.71	O
[	O
95	O
%	O
confidence	I
interval	I
(	O
CI	I
)	O
1.63	O
-	O
1.79	O
]	O
;	O
adjusted	O
hazard	I
ratio	I
(	O
HR	I
)	O
1.41	O
(	O
95	O
%	O
CI	I
1.34	O
-	O
1.48	O
)	O
.	O

By	O
comparison	O
,	O
raloxifene	I
,	O
which	O
is	O
used	O
for	O
the	O
same	O
indication	O
but	O
has	O
a	O
different	O
mechanism	O
of	O
action	O
,	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
heart	I
failure	I
:	O
adjusted	O
HR	I
1.07	O
(	O
95	O
%	O
CI	I
0.76	O
-	O
1.50	O
)	O
.	O

When	O
the	O
two	O
most	O
commonly	O
used	O
bisphosphonates	I
,	O
alendronate	I
and	O
etidronate	I
,	O
were	O
analysed	O
separately	O
,	O
significant	I
trends	O
in	O
the	O
risk	O
of	O
heart	I
failure	I
were	O
observed	O
across	O
refill	O
compliance	I
strata	O
.	O

The	O
risk	O
of	O
heart	I
failure	I
increased	O
significantly	I
with	O
increasing	O
refill	O
compliance	I
for	O
etidronate	I
(	O
P	I
for	O
trend	O
<	O
0.01	O
)	O
,	O
whereas	O
it	O
decreased	O
for	O
alendronate	I
(	O
P	I
for	O
trend	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O

Bisphosphonate	I
users	O
were	O
at	O
increased	O
risk	O
of	O
heart	I
failure	I
compared	O
to	O
age	O
-	O
and	O
gender-matched	O
control	O
subjects	O
.	O

However	O
,	O
users	O
of	O
alendronate	I
showed	O
a	O
dose-dependent	O
reduction	O
in	O
this	O
risk	O
,	O
suggesting	O
that	O
alendronate	I
may	O
reduce	O
the	O
risk	O
of	O
heart	I
failure	I
.	O

Safe	O
,	O
effective	O
off-pump	O
sternal	I
sparing	O
approach	O
for	O
HeartMate	O
II	O
exchange	O
.	O

As	O
left	I
ventricular	I
assist	I
devices	I
(	O
LVADs	I
)	O
have	O
become	O
more	O
widely	O
used	O
for	O
treating	O
patients	I
with	O
advanced	O
heart	I
failure	I
,	O
the	O
incidence	I
of	O
pump	I
dysfunction	I
requiring	O
pump	O
replacement	O
has	O
increased	O
.	O

When	O
dysfunction	I
is	O
due	O
to	O
pump	O
failure	O
or	O
driveline	I
injury	O
,	O
isolated	O
pump	O
replacement	O
can	O
be	O
curative	I
.	O

We	O
have	O
developed	O
a	O
quick	O
,	O
safe	O
pump-exchange	O
technique	O
that	O
avoids	O
a	O
redo	I
sternotomy	I
and	O
cardiopulmonary	I
bypass	I
.	O

We	O
have	O
used	O
this	O
technique	O
to	O
exchange	O
malfunctioning	O
HeartMate	O
II	O
LVADs	I
in	O
14	O
consecutive	O
patients	I
.	O

The	O
patients	I
were	O
extubated	I
within	O
3	O
to	O
6	O
hours	O
,	O
and	O
blood	I
loss	O
and	O
transfusion	I
requirements	O
were	O
nominal	O
.	O

There	O
were	O
no	O
periprocedural	O
deaths	I
or	O
strokes	I
.	O

Clinical	I
characteristics	O
and	O
outcomes	I
of	O
young	O
and	O
very	O
young	O
adults	O
with	O
heart	I
failure	I
:	O
The	O
CHARM	O
programme	O
(	O
Candesartan	I
in	O
Heart	I
Failure	I
Assessment	O
of	O
Reduction	O
in	O
Mortality	I
and	O
Morbidity	I
)	O
.	O

OBJECTIVES	O
:	O

This	O
study	O
sought	O
to	O
determine	O
the	O
characteristics	O
and	O
outcomes	I
of	O
young	O
adults	O
with	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

BACKGROUND	O
:	O

Few	O
studies	O
have	O
focused	O
on	O
young	O
and	O
very	O
young	O
adults	O
with	O
HF	I
.	O

METHODS	O
:	O

Patients	I
were	O
categorized	O
into	O
5	O
age	O
groups	O
:	O
20	O
to	O
39	O
,	O
40	O
to	O
49	O
,	O
50	O
to	O
59	O
,	O
60	O
to	O
69	O
,	O
and	O
≥70	O
years	O
.	O

RESULTS	O
:	O

The	O
youngest	O
patients	I
with	O
HF	I
were	O
more	O
likely	O
to	O
be	O
obese	I
(	O
youngest	O
vs.	O
oldest	O
:	O
body	I
mass	I
index	I
≥35	O
kg	O
/	O
m	O
(	O
2	O
)	O
:	O
23	O
%	O
vs.	O
6	O
%	O
)	O
,	O
of	O
black	O
ethnicity	O
(	O
18	O
%	O
vs.	O
2	O
%	O
)	O
,	O
and	O
have	O
idiopathic-dilated	I
cardiomyopathy	I
(	O
62	O
%	O
vs.	O
9	O
%	O
)	O
(	O
all	O
p	I
<	O
0.0001	O
)	O
.	O

They	O
were	O
less	O
likely	O
to	O
adhere	O
to	O
medication	I
(	O
nonadherence	O
in	O
youngest	O
vs.	O
oldest	O
:	O
24	O
%	O
vs.	O
7	O
%	O
,	O
p	I
=	O
0.001	O
)	O
,	O
salt	O
intake	O
,	O
and	O
other	O
dietary	O
measures	O
(	O
21	O
%	O
vs.	O
9	O
%	O
,	O
p	I
=	O
0.002	O
)	O
.	O

The	O
youngest	O
patients	I
were	O
less	O
likely	O
to	O
have	O
clinical	I
and	O
radiological	I
signs	O
of	O
HF	I
during	O
hospitalization	I
.	O

Quality	I
of	I
life	I
was	O
worse	O
,	O
but	O
all-cause	I
mortality	I
was	O
lowest	O
in	O
the	O
youngest	O
age	O
group	O
(	O
3-year	O
mortality	I
rates	O
across	O
the	O
respective	O
age	O
categories	O
:	O
12	O
%	O
,	O
13	O
%	O
,	O
13	O
%	O
,	O
19	O
%	O
,	O
and	O
31	O
%	O
,	O
respectively	O
)	O
.	O

Compared	O
with	O
the	O
referent	O
age	O
group	O
of	O
60	O
to	O
69	O
years	O
,	O
both	O
all-cause	I
and	O
cardiovascular	I
mortality	I
were	O
lower	O
in	O
the	O
youngest	O
group	O
even	O
after	O
multivariable	I
adjustment	I
(	O
hazard	I
ratio	I
:	O
0.60	O
,	O
95	O
%	O
confidence	I
interval	I
:	O
0.36	O
to	O
1.00	O
;	O
p	I
=	O
0.049	O
,	O
and	O
hazard	I
ratio	I
:	O
0.71	O
,	O
95	O
%	O
confidence	I
interval	I
:	O
0.42	O
to	O
1.18	O
,	O
p	I
=	O
0.186	O
,	O
respectively	O
)	O
.	O

Three-year	O
HF	I
hospitalization	I
rates	O
were	O
24	O
%	O
,	O
15	O
%	O
,	O
15	O
%	O
,	O
22	O
%	O
,	O
and	O
28	O
%	O
in	O
ages	O
20	O
to	O
39	O
,	O
40	O
to	O
49	O
,	O
50	O
to	O
59	O
,	O
60	O
to	O
69	O
,	O
and	O
≥70	O
years	O
,	O
respectively	O
(	O
p	I
<	O
0.0001	O
)	O
.	O

CONCLUSIONS	O
:	O

Beyond	O
divergent	O
etiology	I
and	O
comorbidities	I
,	O
younger	O
patients	I
exhibited	O
striking	O
differences	O
in	O
presentation	O
and	O
outcomes	I
compared	O
with	O
older	O
counterparts	O
.	O

Clinical	I
and	O
radiological	I
signs	O
of	O
HF	I
were	O
less	O
common	O
,	O
yet	O
quality	I
of	I
life	I
was	O
more	O
significantly	I
impaired	O
.	O

Fatal	O
and	O
nonfatal	O
outcomes	I
were	O
discordant	O
,	O
with	O
better	O
survival	O
despite	O
higher	O
hospitalization	I
rates	O
.	O

Unfolded	I
protein	I
response	I
regulates	O
cardiac	I
sodium	I
current	O
in	O
systolic	I
human	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Human	O
heart	I
failure	I
(	O
HF	I
)	O
increases	O
alternative	O
mRNA	I
splicing	I
of	O
the	O
type	O
V	O
,	O
voltage-gated	O
cardiac	I
Na	I
+	I
channel	I
α-subunit	I
(	O
SCN5A	I
)	O
,	O
generating	O
variants	O
encoding	O
truncated	O
,	O
nonfunctional	O
channels	O
that	O
are	O
trapped	O
in	O
the	O
endoplasmic	I
reticulum	I
.	O

In	O
this	O
work	O
,	O
we	O
tested	O
whether	O
truncated	O
Na	I
+	I
channels	I
activate	O
the	O
unfolded	I
protein	I
response	I
(	O
UPR	I
)	O
,	O
contributing	O
to	O
SCN5A	I
electric	O
remodeling	I
in	O
HF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

UPR	I
and	O
SCN5A	I
were	O
analyzed	O
in	O
human	O
ventricular	I
systolic	I
HF	I
tissue	O
samples	O
and	O
human	I
induced	I
pluripotent	I
stem	I
cell-derived	I
cardiomyocytes	I
(	O
hiPSC-CMs	I
)	O
.	O

Cells	I
were	O
exposed	O
to	O
angiotensin	I
II	I
(	O
AngII	I
)	O
and	O
hypoxia	I
,	O
known	O
activators	O
of	O
abnormal	O
SCN5A	I
mRNA	I
splicing	I
,	O
or	O
were	O
induced	O
to	O
overexpress	O
SCN5A	I
variants	O
.	O

UPR	I
effectors	O
,	O
protein	I
kinase	I
R-like	I
ER	I
kinase	I
(	O
PERK	I
)	O
,	O
calreticulin	I
,	O
and	O
CHOP	I
,	O
were	O
increased	O
in	O
human	O
HF	I
tissues	O
.	O

Induction	O
of	O
SCN5A	I
variants	O
with	O
AngII	I
or	O
hypoxia	I
or	O
the	O
expression	I
of	O
exogenous	O
variants	O
induced	O
the	O
UPR	I
with	O
concomitant	O
downregulation	I
of	O
Na	O
+	O
current	O
.	O

PERK	I
activation	O
destabilized	O
SCN5A	I
and	O
,	O
surprisingly	O
,	O
Kv4.3	I
channel	O
mRNAs	I
but	O
not	O
transient	I
receptor	I
potential	I
cation	I
channel	I
M7	I
(	O
TRPM7	I
)	O
channel	O
mRNA	I
.	O

PERK	I
inhibition	O
prevented	O
the	O
loss	O
of	O
full-length	O
SCN5A	I
and	O
Kv4.3	I
mRNA	I
levels	O
resulting	O
from	O
expressing	O
Na	I
+	I
channel	I
mRNA	I
splice	I
variants	O
.	O

CONCLUSIONS	O
:	O

UPR	I
can	O
be	O
initiated	O
by	O
Na	I
+	I
channel	I
mRNA	I
splice	I
variants	O
and	O
is	O
involved	O
in	O
the	O
reduction	O
of	O
cardiac	I
Na	O
+	O
current	O
during	O
human	O
HF	I
.	O

Because	O
the	O
effect	O
is	O
not	O
entirely	O
specific	O
to	O
the	O
SCN5A	I
transcript	O
,	O
the	O
UPR	I
may	O
play	O
an	O
important	O
role	O
in	O
downregulation	I
of	O
multiple	O
cardiac	I
genes	I
in	O
HF	I
.	O

Low-sodium	I
DASH	O
diet	O
improves	O
diastolic	I
function	I
and	O
ventricular-arterial	I
coupling	I
in	O
hypertensive	I
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
.	O

BACKGROUND	O
:	O

Heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFPEF	I
)	O
involves	O
failure	O
of	O
cardiovascular	I
reserve	I
in	O
multiple	O
domains	O
.	O

In	O
HFPEF	I
animal	O
models	O
,	O
dietary	O
sodium	I
restriction	O
improves	O
ventricular	I
and	O
vascular	I
stiffness	I
and	O
function	I
.	O

We	O
hypothesized	O
that	O
the	O
sodium-restricted	I
dietary	O
approaches	O
to	O
stop	O
hypertension	I
diet	O
(	O
DASH	O
/	O
SRD	O
)	O
would	O
improve	O
left	I
ventricular	I
diastolic	I
function	I
,	O
arterial	I
elastance	I
,	O
and	O
ventricular-arterial	I
coupling	I
in	O
hypertensive	I
HFPEF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Thirteen	O
patients	I
with	O
treated	O
hypertension	I
and	O
compensated	I
HFPEF	I
consumed	O
the	O
DASH	O
/	O
SRD	O
(	O
target	O
sodium	I
,	O
50	O
mmol	O
/	O
2100	O
kcal	O
)	O
for	O
21	O
days	O
.	O

We	O
measured	O
baseline	I
and	O
post-DASH	O
/	O
SRD	O
brachial	I
and	O
central	I
blood	I
pressure	I
(	O
via	O
radial	I
arterial	I
tonometry	I
)	O
and	O
cardiovascular	I
function	I
with	O
echocardiographic	I
measures	O
(	O
all	O
previously	O
invasively	I
validated	O
)	O
.	O

Diastolic	I
function	I
was	O
quantified	O
via	O
the	O
parametrized	O
diastolic	I
filling	I
formalism	I
that	O
yields	O
relaxation	O
/	O
viscoelastic	O
(	O
c	O
)	O
and	O
passive	O
/	O
stiffness	O
(	O
k	O
)	O
constants	O
through	O
the	O
analysis	O
of	O
Doppler	I
mitral	I
inflow	I
velocity	I
(	O
E-wave	I
)	O
contours	O
.	O

Effective	O
arterial	I
elastance	I
(	O
Ea	I
)	O
end-systolic	I
elastance	I
(	O
Ees	I
)	O
and	O
ventricular-arterial	I
coupling	I
(	O
defined	O
as	O
the	O
ratio	O
Ees	I
:	O
Ea	I
)	O
were	O
determined	O
using	O
previously	O
published	O
techniques	O
.	O

Wilcoxon	I
matched-pairs	I
signed-rank	I
tests	I
were	O
used	O
for	O
pre-post	O
comparisons	O
.	O

The	O
DASH	O
/	O
SRD	O
reduced	O
clinic	I
and	O
24-hour	O
brachial	I
systolic	I
pressure	I
(	O
155	O
±	O
35	O
to	O
138	O
±	O
30	O
and	O
130	O
±	O
16	O
to	O
123	O
±	O
18	O
mm	O
Hg	O
;	O
both	O
P=0.02	I
)	O
,	O
and	O
central	I
end-systolic	I
pressure	I
trended	O
lower	O
(	O
116	O
±	O
18	O
to	O
111	O
±	O
16	O
mm	O
Hg	O
;	O
P=0.12	I
)	O
.	O

In	O
conjunction	O
,	O
diastolic	I
function	I
improved	O
(	O
c=24.3	O
±	O
5.3	O
to	O
22.7	O
±	O
8.1	O
g	O
/	O
s	O
;	O
P=0.03	I
;	O
k=252	O
±	O
115	O
to	O
170	O
±	O
37	O
g	O
/	O
s	O
(	O
2	O
)	O
;	O
P=0.03	I
)	O
,	O
Ea	I
decreased	O
(	O
2.0	O
±	O
0.4	O
to	O
1.7	O
±	O
0.4	O
mm	O
Hg	O
/	O
mL	O
;	O
P=0.007	I
)	O
,	O
and	O
ventricular-arterial	I
coupling	I
improved	O
(	O
Ees	I
:	O
Ea=1.5	I
±	O
0.3	O
to	O
1.7	O
±	O
0.4	O
;	O
P=0.04	I
)	O
.	O

CONCLUSIONS	O
:	O

In	O
patients	I
with	O
hypertensive	I
HFPEF	I
,	O
the	O
sodium-restricted	I
DASH	O
diet	O
was	O
associated	O
with	O
favorable	O
changes	O
in	O
ventricular	I
diastolic	I
function	I
,	O
arterial	I
elastance	I
,	O
and	O
ventricular-arterial	I
coupling	I
.	O

Presentation	O
,	O
diagnosis	I
,	O
and	O
medical	I
management	O
of	O
heart	I
failure	I
in	O
children	O
:	O
Canadian	O
Cardiovascular	I
Society	O
guidelines	O
.	O

Pediatric	O
heart	I
failure	I
(	O
HF	I
)	O
is	O
an	O
important	O
cause	O
of	O
morbidity	I
and	O
mortality	I
in	O
childhood	O
.	O

This	O
article	O
presents	O
guidelines	O
for	O
the	O
recognition	O
,	O
diagnosis	I
,	O
and	O
early	O
medical	I
management	O
of	O
HF	I
in	O
infancy	O
,	O
childhood	O
,	O
and	O
adolescence	O
.	O

The	O
guidelines	O
are	O
intended	O
to	O
assist	O
practitioners	O
in	O
office-based	O
or	O
emergency	I
room	I
practice	O
,	O
who	O
encounter	O
children	O
with	O
undiagnosed	I
heart	I
disease	I
and	O
symptoms	I
of	O
possible	O
HF	I
,	O
rather	O
than	O
those	O
who	O
have	O
already	O
received	O
surgical	I
palliation	I
.	O

The	O
guidelines	O
have	O
been	O
developed	O
using	O
the	O
Grading	O
of	O
Recommendations	O
Assessment	O
,	O
Development	O
and	O
Evaluation	O
(	O
GRADE	O
)	O
methodology	O
,	O
and	O
are	O
accompanied	O
by	O
practical	O
Recommendations	O
for	O
their	O
application	O
in	O
the	O
clinical	I
setting	O
,	O
supplemented	O
by	O
online	O
material	O
.	O

This	O
work	O
does	O
not	O
include	O
Recommendations	O
for	O
advanced	O
management	O
involving	O
ventricular	I
assist	I
devices	I
,	O
or	O
other	O
device	O
therapies	I
.	O

Reasons	O
for	O
not	O
prescribing	I
guideline-recommended	O
medications	I
to	O
adults	O
with	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Little	O
is	O
known	O
about	O
how	O
often	O
contextual	O
factors	O
such	O
as	O
patient	I
preferences	O
and	O
competing	O
priorities	O
impact	O
prescribing	I
of	O
guideline-recommended	O
medications	I
,	O
or	O
about	O
the	O
extent	O
to	O
which	O
these	O
factors	O
are	O
documented	O
in	O
medical	I
records	O
and	O
available	O
to	O
performance	O
measurement	O
systems	O
.	O

METHODS	O
:	O

Mixed-methods	I
study	I
of	O
295	O
veterans	O
aged	O
50	O
years	O
and	O
older	O
in	O
4	O
VA	O
health	I
care	I
systems	O
who	O
had	O
systolic	I
heart	I
failure	I
and	O
were	O
not	O
prescribed	I
a	O
β-blocker	I
and	O
/	O
or	O
an	O
angiotensin	I
converting	I
enzyme	I
inhibitor	I
or	O
angiotensin-receptor	I
blocker	I
.	O

Reasons	O
for	O
nontreatment	O
were	O
identified	O
from	O
clinic	I
notes	O
and	O
from	O
interviews	O
with	O
62	O
primary	O
care	O
clinicians	I
caring	O
for	O
these	O
patients	I
.	O

These	O
reasons	O
were	O
classified	O
using	O
a	O
published	O
taxonomy	O
.	O

RESULTS	O
:	O

Among	O
295	O
patients	I
not	O
receiving	O
guideline-recommended	O
drugs	I
for	O
heart	I
failure	I
,	O
chart	O
review	O
identified	O
biomedical	I
reasons	O
for	O
nonprescribing	I
in	O
42%-58	O
%	O
of	O
patients	I
and	O
contextual	O
reasons	O
in	O
11%-17	O
%	O
.	O

Clinician	I
interviews	O
identified	O
twice	O
as	O
many	O
reasons	O
for	O
nonprescribing	I
as	O
chart	O
review	O
(	O
mean	O
1.6	O
vs.	O
0.8	O
reasons	O
per	O
patient	I
,	O
P	I
<	O
0.001	O
)	O
.	O

In	O
these	O
interviews	O
,	O
biomedical	I
reasons	O
for	O
nonprescribing	I
were	O
cited	O
in	O
50%-70	O
%	O
of	O
patients	I
,	O
and	O
contextual	O
reasons	O
in	O
64%-70	O
%	O
.	O

The	O
most	O
common	O
contextual	O
reasons	O
were	O
comanagement	O
with	O
other	O
clinicians	I
(	O
32%-35	O
%	O
of	O
patients	I
)	O
,	O
patient	I
preferences	O
and	O
nonadherence	O
(	O
15%-24	O
%	O
)	O
,	O
and	O
clinician	I
belief	O
that	O
the	O
medication	I
is	O
not	O
indicated	O
in	O
the	O
patient	I
(	O
12%-20	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O

Contextual	O
reasons	O
for	O
not	O
prescribing	I
angiotensin	I
converting	I
enzyme	I
inhibitor	I
/	O
angiotensin-receptor	I
blockers	I
and	O
β-blockers	I
are	O
present	O
in	O
two	O
thirds	O
of	O
patients	I
with	O
heart	I
failure	I
who	O
did	O
not	O
receive	O
these	O
medications	I
,	O
yet	O
are	O
poorly	O
documented	O
in	O
medical	I
records	O
.	O

The	O
structure	O
of	O
medical	I
records	O
should	O
be	O
improved	O
to	O
facilitate	O
documentation	O
of	O
contextual	O
reasons	O
for	O
not	O
providing	O
guideline-recommended	O
care	O
.	O

Effects	O
of	O
biventricular	I
pacing	I
on	O
left	I
heart	I
twist	I
and	O
strain	I
in	O
a	O
porcine	O
model	O
of	O
right	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Biventricular	I
pacing	I
(	O
BiVP	I
)	O
improves	O
cardiac	I
output	I
(	O
CO	I
)	O
in	O
selected	O
cardiac	I
surgery	I
patients	I
,	O
but	O
response	O
remains	O
variable	O
,	O
necessitating	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
.	O

Accordingly	O
,	O
we	O
used	O
speckle	I
tracking	I
echocardiography	I
(	O
STE	I
)	O
to	O
analyze	O
BiVP	I
during	O
acute	I
right	I
ventricular	I
pressure	I
overload	I
(	O
RVPO	I
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

In	O
nine	O
pigs	O
,	O
the	O
inferior	I
vena	I
cava	I
(	O
IVC	I
)	O
was	O
snared	O
to	O
decrease	O
CO	I
and	O
establish	O
a	O
control	O
model	O
.	O

Heart	I
block	I
was	O
induced	O
,	O
the	O
pulmonary	I
artery	I
snared	O
,	O
and	O
BiVP	I
initiated	O
.	O

Echocardiograms	I
of	O
the	O
left	I
ventricular	I
midpapillary	I
level	O
were	O
taken	O
at	O
varying	O
atrioventricular	I
delay	I
(	O
AVD	I
)	O
and	O
interventricular	I
delay	I
(	O
VVD	I
)	O
for	O
STE	I
analysis	O
of	O
regional	O
circumferential	I
strain	I
(	O
CS	I
)	O
and	O
radial	I
strain	I
(	O
RS	I
)	O
.	O

Echocardiograms	I
were	O
taken	O
of	O
the	O
left	I
ventricular	I
base	I
,	O
midpapillary	I
,	O
and	O
apex	I
during	O
baseline	I
,	O
IVC	I
occlusion	I
,	O
and	O
each	O
BiVP	I
setting	O
for	O
STE	I
analysis	O
of	O
twist	O
,	O
apical	O
and	O
basal	O
rotations	O
,	O
CS	I
,	O
RS	I
,	O
and	O
synchrony	O
.	O

Indices	O
were	O
correlated	I
against	O
CO	I
with	O
mixed	I
linear	I
models	I
.	O

RESULTS	O
:	O

During	O
IVC	I
occlusion	I
,	O
CO	I
correlated	I
with	O
twist	O
,	O
apical	O
rotation	O
,	O
RS	I
,	O
RS	I
synchrony	I
,	O
and	O
CS	I
(	O
P	I
<	O
0.05	O
)	O
.	O

During	O
RVPO	I
with	O
BiVP	I
,	O
CO	I
only	O
correlated	I
with	O
RS	I
synchrony	I
and	O
CS	I
(	O
P	I
<	O
0.05	O
)	O
.	O

During	O
AVD	I
and	O
VVD	I
variations	O
,	O
CO	I
was	O
associated	O
with	O
free	I
wall	I
RS	I
(	O
P	I
<	O
0.008	O
)	O
.	O

CO	I
correlated	I
with	O
septal	I
wall	O
CS	I
during	O
AVD	I
variation	O
and	O
free	I
wall	I
CS	I
during	O
VVD	I
variation	O
(	O
P	I
<	O
0.008	O
)	O
.	O

CONCLUSIONS	O
:	O

In	O
an	O
open	O
chest	I
model	O
,	O
twist	O
,	O
RS	I
,	O
RS	I
synchrony	I
,	O
and	O
CS	I
analyzed	O
by	O
STE	I
may	O
be	O
noninvasive	I
surrogates	O
for	O
changes	O
in	O
CO.	I
During	O
RVPO	I
,	O
changes	O
in	O
RS	I
synchrony	I
and	O
CS	I
with	O
varying	O
regional	O
strain	I
contributions	O
may	O
be	O
the	O
primary	O
mechanism	O
in	O
which	O
BiVP	I
improves	O
CO.	I
Lack	O
of	O
correlation	I
of	O
remaining	O
indices	O
may	O
reflect	O
postsystolic	I
function	I
.	O

MicroRNAs	I
in	O
heart	I
failure	I
:	O
new	O
targets	O
in	O
disease	I
management	O
.	O

Heart	I
failure	I
is	O
the	O
leading	O
cause	O
of	O
mortality	I
in	O
Western	O
society	O
and	O
represents	O
the	O
fastest	O
growing	O
subclass	O
of	O
cardiovascular	I
diseases	I
.	O

An	O
increasing	O
body	O
of	O
evidence	O
indicates	O
an	O
important	O
role	O
for	O
microRNAs	I
(	O
miRNAs	I
)	O
in	O
the	O
pathogenesis	I
and	O
progression	O
of	O
heart	I
failure.	I
miRNAs	I
are	O
small	O
noncoding	O
RNAs	I
that	O
regulate	O
expression	I
of	O
target	O
genes	I
by	O
sequence-specific	O
binding	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
messenger	I
RNA	I
,	O
which	O
results	O
in	O
degradation	O
or	O
translational	O
repression	O
.	O

To	O
date	O
,	O
many	O
miRNAs	I
(	O
and	O
their	O
targets	O
)	O
that	O
play	O
a	O
role	O
in	O
diverse	O
aspects	O
of	O
cardiac	I
remodeling	I
and	O
heart	I
failure	I
development	O
have	O
been	O
identified	O
.	O

Here	O
,	O
we	O
give	O
an	O
overview	O
of	O
these	O
miRNAs	I
and	O
their	O
role	O
in	O
cardiac	I
pathogenesis	I
.	O

In	O
addition	O
,	O
we	O
provide	O
brief	O
insight	O
into	O
the	O
potential	O
of	O
miRNAs	I
as	O
novel	O
therapeutic	I
targets	O
for	O
heart	I
failure	I
.	O

Testosterone	I
therapy	I
during	O
exercise	I
rehabilitation	I
in	O
male	O
patients	I
with	O
chronic	I
heart	I
failure	I
who	O
have	O
low	O
testosterone	I
status	O
:	O
a	O
double-blind	I
randomized	I
controlled	O
feasibility	O
study	O
.	O

BACKGROUND	O
:	O

This	O
study	O
assessed	O
the	O
feasibility	O
of	O
a	O
12-week	O
program	O
of	O
exercise	O
,	O
with	O
and	O
without	O
intramuscular	I
testosterone	I
supplementation	I
,	O
in	O
male	O
patients	I
with	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
and	O
low	O
testosterone	I
status	O
and	O
collected	O
preliminary	O
data	O
for	O
key	O
health	I
outcomes	I
.	O

METHODS	O
:	O

Male	O
patients	I
with	O
CHF	I
(	O
n	O
=	O
41	O
,	O
age	O
67.2	O
years	O
,	O
range	O
51	O
-	O
84	O
years	O
)	O
with	O
mean	O
±	O
SD	I
testosterone	I
levels	O
of	O
10.7	O
±	O
2.6	O
nmol	O
/	O
L	O
(	O
309	O
±	O
76	O
ng	O
/	O
dL	O
)	O
were	O
randomly	O
allocated	O
to	O
exercise	O
with	O
testosterone	I
or	O
placebo	I
groups	O
.	O

Feasibility	O
was	O
assessed	O
in	O
terms	O
of	O
recruitment	O
,	O
intervention	O
compliance	I
,	O
and	O
attrition	I
.	O

Outcomes	I
included	O
an	O
incremental	I
shuttle	I
walk	I
test	I
,	O
peak	I
oxygen	I
uptake	I
,	O
muscular	I
strength	O
,	O
echocardiographic	I
measures	O
,	O
N-terminal	I
pro-brain	I
natriuretic	I
peptide	I
,	O
inflammatory	I
markers	O
,	O
depression	O
(	O
Beck	O
Depression	O
Inventory	O
)	O
,	O
and	O
health-related	I
quality	I
of	I
life	I
(	O
Minnesota	O
Living	O
with	O
Heart	I
Failure	I
Questionnaire	O
and	O
Medical	I
Outcomes	I
Study	O
Short-Form	O
)	O
.	O

RESULTS	O
:	O

Attrition	I
was	O
30	O
%	O
but	O
with	O
100	O
%	O
compliance	I
to	O
exercise	O
and	O
injections	I
in	O
patients	I
who	O
completed	O
the	O
study	O
.	O

Similar	O
improvements	O
in	O
shuttle	I
walk	I
test	I
(	O
18	O
%	O
vs	O
19	O
%	O
)	O
,	O
body	O
mass	O
(	O
-	O
1.3	O
kg	O
vs	O
-	O
1.0	O
kg	O
)	O
,	O
and	O
hand	O
grip	O
strength	O
(	O
2.1	O
kg	O
vs	O
2.5	O
kg	O
)	O
from	O
baseline	I
were	O
observed	O
in	O
both	O
groups	O
.	O

The	O
exercise	O
with	O
testosterone	I
group	O
showed	O
improvements	O
from	O
baseline	I
in	O
peak	I
oxygen	I
uptake	I
(	O
P	I
<	O
.01	O
)	O
,	O
Beck	O
Depression	O
Inventory	O
(	O
P	I
<	O
.05	O
)	O
,	O
leg	O
strength	O
(	O
P	I
<	O
.05	O
)	O
,	O
and	O
several	O
Medical	I
Outcomes	I
Study	O
Short-Form	O
quality	I
of	I
life	I
domains	O
(	O
P	I
<	O
.05	O
)	O
,	O
which	O
were	O
generally	O
not	O
apparent	O
in	O
the	O
exercise	O
with	O
placebo	I
group	O
.	O

Echocardiographic	I
measures	O
,	O
N-terminal	I
pro-brain	I
natriuretic	I
peptide	I
,	O
and	O
inflammatory	I
markers	O
were	O
mostly	O
unchanged	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
shows	O
for	O
the	O
first	O
time	O
that	O
testosterone	I
supplementation	I
during	O
a	O
program	O
of	O
exercise	I
rehabilitation	I
is	O
feasible	O
and	O
can	O
positively	O
impact	O
on	O
a	O
range	O
of	O
key	O
health	I
outcomes	I
in	O
elderly	O
male	O
patients	I
with	O
CHF	I
who	O
have	O
a	O
low	O
testosterone	I
status	O
.	O

Risk	O
factors	O
and	O
outcomes	I
associated	O
with	O
the	O
development	O
of	O
myocardial	I
ischemic	I
events	I
in	O
patients	I
who	O
receive	O
cardiac	I
resynchronization	I
therapy	I
.	O

There	O
are	O
limited	O
data	O
regarding	O
risk	O
factors	O
for	O
the	O
development	O
of	O
ischemic	I
events	I
(	O
IEs	I
)	O
among	O
patients	I
with	O
ischemic	I
cardiomyopathy	I
(	O
IC	I
)	O
who	O
receive	O
cardiac	I
resynchronization	I
therapy	I
with	O
a	O
defibrillator	I
(	O
CRT-D	I
)	O
and	O
their	O
effect	O
on	O
the	O
efficacy	O
of	O
the	O
device	O
.	O

The	O
present	O
study	O
population	O
comprised	O
1,045	O
patients	I
with	O
IC	I
enrolled	O
in	O
the	O
Multicenter	O
Automatic	O
Defibrillator	I
Implantation	I
Trial-Cardiac	I
Resynchronization	I
Therapy	I
.	O

We	O
used	O
multivariate	I
Cox	I
proportional	I
hazards	I
regression	I
modeling	I
to	O
identify	O
risk	O
factors	O
for	O
the	O
development	O
of	O
IE	I
(	O
comprising	O
hospitalization	I
for	O
acute	I
coronary	I
syndromes	I
and	O
/	O
or	O
coronary	I
interventions	I
during	O
the	O
trial	O
)	O
among	O
study	O
patients	I
.	O

Time-dependent	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
effect	O
of	O
IE	I
on	O
the	O
risk	O
for	O
subsequent	O
heart	I
failure	I
(	O
HF	I
)	O
or	O
death	I
in	O
CRT-D	I
recipients	O
.	O

Independent	O
predictors	O
for	O
the	O
development	O
of	O
IE	I
among	O
study	O
patients	I
included	O
previous	O
revascularization	I
(	O
coronary	I
artery	I
bypass	I
surgery	I
:	O
hazard	I
ratio	I
[	O
HR	I
]	O
1.88	O
,	O
p	I
=	O
0.003	O
;	O
percutaneous	I
coronary	I
intervention	I
:	O
HR	I
3.21	O
,	O
p	I
<	O
0.001	O
)	O
and	O
increased	O
systolic	I
blood	I
pressure	I
(	O
HR	I
1.67	O
,	O
p	I
=	O
0.02	O
)	O
,	O
whereas	O
a	O
left	I
bundle	I
branch	I
block	I
pattern	I
on	O
the	O
baseline	I
electrocardiogram	I
was	O
associated	O
with	O
reduced	O
risk	O
for	O
IE	I
(	O
HR	I
0.62	O
,	O
p	I
=	O
0.02	O
)	O
.	O

Treatment	O
with	O
CRT-D	I
did	O
not	O
have	O
a	O
significant	I
effect	O
on	O
IE	I
risk	O
compared	O
with	O
defibrillator-only	I
therapy	I
(	O
HR	I
0.87	O
,	O
p	I
=	O
0.51	O
)	O
.	O

Time-dependent	O
analysis	O
showed	O
that	O
the	O
development	O
of	O
IEs	I
among	O
CRT-D	I
recipients	O
was	O
associated	O
with	O
more	O
than	O
twofold	O
(	O
p	I
=	O
0.01	O
)	O
increased	O
risk	O
for	O
subsequent	O
heart	I
failure	I
or	O
death	I
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
treatment	O
with	O
CRT-D	I
does	O
not	O
reduce	O
the	O
risk	O
of	O
IE	I
in	O
patients	I
with	O
IC	I
and	O
that	O
the	O
benefit	O
of	O
CRT-D	I
is	O
attenuated	O
after	O
the	O
development	O
of	O
IEs	I
in	O
this	O
population	O
.	O

Cardiac	I
magnetic	I
resonance	I
postcontrast	I
T1	I
time	I
is	O
associated	O
with	O
outcome	I
in	O
patients	I
with	O
heart	I
failure	I
and	O
preserved	I
ejection	I
fraction	I
.	O

BACKGROUND	O
:	O

The	O
underlying	O
pathophysiology	I
of	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFPEF	I
)	O
is	O
incompletely	O
understood	O
,	O
but	O
myocardial	I
extracellular	I
matrix	I
accumulation	O
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
.	O

Our	O
aims	O
were	O
to	O
estimate	O
myocardial	I
extracellular	I
matrix	I
using	O
cardiac	I
magnetic	I
resonance	I
T1	I
mapping	I
and	O
to	O
assess	O
the	O
relationship	O
between	O
pathobiology	I
/	O
pathophysiology	I
and	O
prognosis	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Patients	I
with	O
suspected	O
HFPEF	I
(	O
n=100	O
)	O
were	O
enrolled	O
in	O
this	O
prospective	I
,	O
observational	O
study	O
.	O

Confirmatory	O
diagnostic	I
tests	O
,	O
cardiac	I
magnetic	I
resonance	I
imaging	I
including	O
T1	I
mapping	I
,	O
and	O
invasive	I
hemodynamic	I
assessments	I
were	O
performed	O
at	O
baseline	I
.	O

Sixty-one	O
patients	I
with	O
confirmed	O
HFPEF	I
entered	O
a	O
longitudinal	I
outcome-monitoring	I
phase	O
(	O
mean	O
,	O
22.9±5.0	O
months	O
)	O
,	O
during	O
which	O
16	O
had	O
a	O
cardiac	I
event	I
.	O

Cardiac	I
magnetic	I
resonance	I
T1	I
time	I
(	O
hazard	I
ratio	I
,	O
0.99	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.98	O
-	O
0.99	O
;	O
P=0.046	I
)	O
,	O
left	I
atrial	I
area	I
(	O
hazard	I
ratio	I
,	O
1.08	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
1.03	O
-	O
1.13	O
;	O
P	I
<	O
0.01	O
)	O
,	O
and	O
pulmonary	I
vascular	I
resistance	I
(	O
hazard	I
ratio	I
,	O
1.01	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
1.00	O
-	O
1.01	O
;	O
P=0.03	I
)	O
were	O
significantly	I
associated	O
with	O
cardiac	I
events	I
.	O

Patients	I
with	O
T1	I
times	I
below	O
the	O
median	O
(	O
<	O
388.3	O
ms	O
)	O
were	O
at	O
greater	O
risk	O
of	O
cardiac	I
events	I
than	O
the	O
rest	O
of	O
the	O
group	O
(	O
P	I
<	O
0.01	O
)	O
.	O

Extracellular	I
matrix	I
of	O
left	I
ventricular	I
biopsies	I
(	O
n=9	O
)	O
,	O
quantified	O
by	O
TissueFAXS	O
technology	O
correlated	I
with	O
T1	I
time	I
(	O
R=0.98	I
;	O
P	I
<	O
0.01	O
)	O
.	O

T1	I
time	I
also	O
correlated	I
with	O
right	I
ventricular-pulmonary	I
arterial	I
coupling	I
(	O
pulmonary	I
vascular	I
resistance	I
:	O
R=-0.36	I
;	O
P	I
<	O
0.01	O
;	O
right	I
ventricular	I
ejection	I
fraction	I
:	O
R=0.28	I
;	O
P=0.01	I
)	O
.	O

CONCLUSIONS	O
:	O

In	O
the	O
present	O
preliminary	O
study	O
,	O
cardiac	I
magnetic	I
resonance	I
postcontrast	I
T1	I
time	I
is	O
associated	O
with	O
prognosis	I
in	O
HFPEF	I
,	O
suggesting	O
postcontrast	I
T1	I
as	O
possible	O
biomarker	I
for	O
HFPEF	I
.	O

Multiacquisition	O
T1-mapping	I
MRI	I
during	O
tidal	I
respiration	I
for	O
quantification	O
of	O
myocardial	I
T1	I
in	O
swine	O
with	O
heart	I
failure	I
.	O

OBJECTIVE	O
:	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
evaluate	O
a	O
free-breathing	I
pulse	I
sequence	O
to	O
quantify	O
myocardial	I
T1	I
changes	O
in	O
a	O
swine	O
model	O
of	O
tachycardia-induced	I
heart	I
failure	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

Yorkshire	O
swine	O
were	O
implanted	I
with	O
pacemakers	I
and	O
were	O
ventricularly	I
paced	O
at	O
200	O
beats	O
/	O
min	O
to	O
induce	O
heart	I
failure	I
.	O

Animals	O
were	O
scanned	O
twice	O
with	O
a	O
1.5-T	O
MRI	I
scanner	I
,	O
once	O
at	O
baseline	I
and	O
once	O
at	O
heart	I
failure	I
.	O

A	O
T1-mapping	I
sequence	O
was	O
performed	O
during	O
tidal	I
respiration	I
before	O
and	O
5	O
minutes	O
after	O
the	O
administration	O
of	O
a	O
gadolinium-chelate	I
contrast	I
agent	I
.	O

T1-mapping	I
values	O
were	O
compared	O
between	O
the	O
baseline	I
and	O
heart	I
failure	I
scans	O
.	O

The	O
percentage	O
of	O
fibrosis	I
of	O
heart	I
failure	I
myocardial	I
tissue	I
was	O
compared	O
with	O
similar	O
left	I
ventricular	I
tissue	O
from	O
control	O
animals	O
using	O
trichrome	I
blue	I
histologic	I
analysis	I
.	O

RESULTS	O
:	O

In	O
the	O
study	O
cohort	O
,	O
differences	O
were	O
found	O
between	O
the	O
baseline	I
and	O
heart	I
failure	I
T1-mapping	I
values	O
before	O
the	O
administration	O
of	O
contrast	O
agent	O
(	O
960	O
±	O
96	O
and	O
726	O
±	O
94	O
ms	O
,	O
respectively	O
;	O
p	I
=	O
0.02	O
)	O
and	O
after	O
contrast	O
agent	O
administration	O
(	O
546	O
±	O
180	O
and	O
300	O
±	O
171	O
ms	O
,	O
respectively	O
;	O
p	I
=	O
0.005	O
)	O
.	O

The	O
animals	O
with	O
heart	I
failure	I
also	O
had	O
a	O
difference	O
histologically	I
in	O
the	O
percentage	O
of	O
myocardial	I
collagen	I
compared	O
with	O
tissue	O
from	O
healthy	I
control	O
animals	O
(	O
control	O
,	O
5.4	O
%	O
±	O
1.0	O
%	O
;	O
heart	I
failure	I
,	O
9.4	O
%	O
±	O
1.6	O
%	O
;	O
p	I
<	O
0.001	O
)	O
.	O

CONCLUSION	O
:	O

The	O
proposed	O
T1-mapping	I
technique	O
can	O
quantify	O
diffuse	O
myocardial	I
changes	O
associated	O
with	O
heart	I
failure	I
without	O
the	O
use	O
of	O
a	O
contrast	O
agent	O
and	O
without	O
breath-holding	O
.	O

These	O
T1	I
changes	O
appear	O
to	O
be	O
associated	O
with	O
increases	O
in	O
the	O
percentage	O
of	O
myocardial	I
collagen	I
that	O
in	O
this	O
study	O
were	O
not	O
detected	O
by	O
traditional	O
myocardial	I
delayed	O
enhancement	O
imaging	O
.	O

T1	I
mapping	I
may	O
be	O
a	O
useful	O
technique	O
for	O
detecting	O
early	O
but	O
clinically	I
significant	I
myocardial	I
fibrosis	I
.	O

Heart	I
failure	I
:	O
a	O
disease	I
complex	O
with	O
challenging	O
therapeutics	I
.	O

Heart	I
failure	I
(	O
HF	I
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
cardiovascular	I
hospitalization	I
,	O
especially	O
among	O
the	O
elderly	O
.	O

It	O
has	O
a	O
higher	O
mortality	I
and	O
morbidity	I
than	O
several	O
cancers	O
and	O
consumes	O
a	O
significant	O
portion	O
of	O
the	O
health-care	I
budget	O
.	O

HF	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
is	O
commoner	O
among	O
women	O
who	O
may	O
have	O
underlying	O
hypertension	I
.	O

Significant	O
progress	O
has	O
been	O
achieved	O
in	O
the	O
development	O
of	O
lifesaving	O
drugs	I
for	O
HF	I
with	I
reduced	I
ejection	I
fraction	I
(	O
HFrEF	I
)	O
.	O

However	O
,	O
treatment	O
of	O
HFpEF	I
still	O
poses	O
significant	O
challenges	O
.	O

Comparison	O
of	O
predictors	O
of	O
heart	I
failure-related	I
hospitalization	I
or	O
death	I
in	O
patients	I
with	O
versus	O
without	O
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
.	O

Heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
is	O
recognized	O
as	O
a	O
major	O
cause	O
of	O
cardiovascular	I
morbidity	I
and	O
mortality	I
.	O

An	O
ability	O
to	O
identify	O
patients	I
with	O
HFpEF	I
who	O
are	O
at	O
increased	O
risk	O
for	O
adverse	I
outcomes	I
can	O
facilitate	O
their	O
more	O
careful	O
management	O
.	O

We	O
studied	O
the	O
patients	I
having	O
heart	I
failure	I
(	O
HF	I
)	O
using	O
data	O
from	O
the	O
Heart	I
Failure	I
Adherence	O
and	O
Retention	O
Trial	O
(	O
HART	O
)	O
.	O

HART	O
enrolled	O
902	O
patients	I
in	O
the	O
New	O
York	O
Heart	I
Association	O
(	O
NYHA	I
)	I
class	I
II	I
or	O
III	I
who	O
had	O
been	O
recently	O
hospitalized	I
for	O
HF	I
to	O
study	O
the	O
impact	O
of	O
self-management	O
counseling	O
on	O
the	O
primary	I
outcome	I
of	O
death	I
or	O
HF	I
hospitalization	I
.	O

In	O
HART	O
,	O
208	O
patients	I
had	O
HFpEF	I
and	O
692	O
had	O
HF	I
with	I
reduced	I
ejection	I
fraction	I
(	O
HFrEF	I
)	O
and	O
were	O
followed	O
for	O
a	O
median	O
of	O
1,080	O
days	O
.	O

Two	O
final	O
multivariate	I
models	I
were	O
developed	O
.	O

In	O
patients	I
having	O
HFpEF	I
,	O
predictors	O
of	O
primary	I
outcome	I
were	O
male	O
gender	O
(	O
odds	I
ratio	I
[	O
OR	I
]	O
3.45	O
,	O
p	I
=	O
0.004	O
)	O
,	O
NYHA	I
class	I
III	I
(	O
OR	I
3.05	O
,	O
p	I
=	O
0.008	O
)	O
,	O
distance	O
covered	O
on	O
a	O
6-minute	I
walk	I
test	I
(	O
6-MWT	I
)	O
of	O
<	O
620	O
feet	O
(	O
OR	I
2.81	O
,	O
p	I
=	O
0.013	O
)	O
,	O
and	O
<	O
80	O
%	O
adherence	O
to	O
prescribed	I
medications	I
(	O
OR	I
2.61	O
,	O
p	I
=	O
0.018	O
)	O
.	O

In	O
patients	I
having	O
HFrEF	I
,	O
the	O
predictors	O
were	O
being	O
on	O
diuretics	I
(	O
OR	I
3.06	O
,	O
p	I
=	O
0.001	O
)	O
,	O
having	O
≥3	O
co-morbidities	I
(	O
OR	I
2.11	O
,	O
p	I
=	O
0.0001	O
)	O
,	O
distance	O
covered	O
on	O
a	O
6-MWT	I
of	O
<	O
620	O
feet	O
(	O
OR	I
1.94	O
,	O
p	I
=	O
0.001	O
)	O
,	O
NYHA	I
class	I
III	I
(	O
OR	I
1.90	O
,	O
p	I
=	O
0.001	O
)	O
,	O
and	O
age	O
>	O
65	O
years	O
(	O
OR	I
1.63	O
,	O
p	I
=	O
0.01	O
)	O
.	O

In	O
conclusion	O
,	O
indicators	O
of	O
functional	I
status	I
(	O
6-MWT	I
and	O
NYHA	I
class	I
)	O
were	O
common	O
to	O
both	O
patients	I
with	O
HFpEF	I
and	O
those	O
with	O
HFrEF	I
,	O
whereas	O
gender	O
and	O
adherence	O
to	O
prescribed	I
therapy	I
were	O
unique	O
to	O
patients	I
having	O
HFpEF	I
in	O
predicting	O
death	I
or	O
HF	I
hospitalization	I
.	O

Increase	O
in	O
parasympathetic	I
tone	I
by	O
pyridostigmine	I
prevents	O
ventricular	I
dysfunction	I
during	O
the	O
onset	O
of	O
heart	I
failure	I
.	O

Heart	I
failure	I
(	O
HF	I
)	O
is	O
characterized	O
by	O
elevated	O
sympathetic	I
activity	I
and	O
reduced	O
parasympathetic	I
control	I
of	O
the	O
heart	I
.	O

Experimental	O
evidence	O
suggests	O
that	O
the	O
increase	O
in	O
parasympathetic	I
function	O
can	O
be	O
a	O
therapeutic	I
alternative	O
to	O
slow	O
HF	I
evolution	O
.	O

The	O
parasympathetic	I
neurotransmission	I
can	O
be	O
improved	O
by	O
acetylcholinesterase	I
inhibition	I
.	O

We	O
investigated	O
the	O
long-term	O
(	O
4	O
wk	O
)	O
effects	O
of	O
the	O
acetylcholinesterase	I
inhibitor	I
pyridostigmine	I
on	O
sympathovagal	I
balance	I
,	O
cardiac	I
remodeling	I
,	O
and	O
cardiac	I
function	I
in	O
the	O
onset	O
of	O
HF	I
following	O
myocardial	I
infarction	I
.	O

Myocardial	I
infarction	I
was	O
elicited	O
in	O
adult	O
male	O
Wistar	O
rats	O
.	O

After	O
4	O
wk	O
of	O
pyridostigmine	I
administration	O
,	O
per	O
os	O
,	O
methylatropine	I
and	O
propranolol	I
were	O
used	O
to	O
evaluate	O
the	O
cardiac	I
sympathovagal	I
balance	I
.	O

The	O
tachycardic	I
response	O
caused	O
by	O
methylatropine	I
was	O
considered	O
to	O
be	O
the	O
vagal	I
tone	I
,	O
whereas	O
the	O
bradycardic	I
response	O
caused	O
by	O
propranolol	I
was	O
considered	O
to	O
be	O
the	O
sympathetic	I
tone	I
.	O

In	O
conscious	O
HF	I
rats	O
,	O
pyridostigmine	I
reduced	O
the	O
basal	I
heart	I
rate	I
,	O
increased	O
vagal	I
,	O
and	O
reduced	O
sympathetic	I
control	I
of	I
heart	I
rate	I
.	O

Pyridostigmine	I
reduced	O
the	O
myocyte	I
diameter	O
and	O
collagen	I
density	O
of	O
the	O
surviving	O
left	I
ventricle	I
.	O

Pyridostigmine	I
also	O
increased	O
vascular	I
endothelial	I
growth	I
factor	I
protein	I
in	O
the	O
left	I
ventricle	I
,	O
suggesting	O
myocardial	I
angiogenesis	I
.	O

Cardiac	I
function	I
was	O
assessed	O
by	O
means	O
of	O
the	O
pressure-volume	O
conductance	O
catheter	I
system	O
.	O

HF	I
rats	O
treated	O
with	O
pyridostigmine	I
exhibited	O
a	O
higher	O
stroke	I
volume	I
,	O
ejection	I
fraction	I
,	O
cardiac	I
output	I
,	O
and	O
contractility	I
of	O
the	O
left	I
ventricle	I
.	O

It	O
was	O
demonstrated	O
that	O
the	O
long-term	O
administration	O
of	O
pyridostigmine	I
started	O
right	O
after	O
coronary	I
artery	I
ligation	I
augmented	O
cardiac	I
vagal	I
and	O
reduced	O
sympathetic	I
tone	I
,	O
attenuating	O
cardiac	I
remodeling	I
and	O
left	I
ventricular	I
dysfunction	I
during	O
the	O
progression	O
of	O
HF	I
in	O
rats	O
.	O

Risk	O
for	O
Hospitalized	I
Heart	I
Failure	I
Among	O
New	O
Users	O
of	O
Saxagliptin	I
,	O
Sitagliptin	I
,	O
and	O
Other	O
Antihyperglycemic	I
Drugs	I
:	O
A	O
Retrospective	I
Cohort	I
Study	I
.	O

BACKGROUND	O
:	O

Recent	O
postmarketing	O
trials	O
produced	O
conflicting	O
results	O
about	O
the	O
risk	O
for	O
hospitalized	I
heart	I
failure	I
(	O
hHF	O
)	O
associated	O
with	O
dipeptidyl	I
peptidase-4	I
(	O
DPP-4	I
)	O
inhibitors	I
,	O
creating	O
uncertainty	O
about	O
the	O
safety	O
of	O
these	O
antihyperglycemic	I
agents	I
.	O

OBJECTIVE	O
:	O

To	O
examine	O
the	O
associations	O
of	O
hHF	O
with	O
saxagliptin	I
and	O
sitagliptin	I
.	O

DESIGN	O
:	O

Population-based	O
,	O
retrospective	O
,	O
new-user	O
cohort	I
study	I
.	O

SETTING	O
:	O

18	O
health	I
insurance	O
and	O
health	I
system	O
data	O
partners	O
in	O
the	O
U.S.	O
Food	O
and	O
Drug	I
Administration	O
's	O
Mini-Sentinel	O
program	O
.	O

PATIENTS	I
:	O

Patients	I
aged	O
18	O
years	O
or	O
older	O
with	O
type	I
2	I
diabetes	I
who	O
initiated	O
therapy	I
with	O
saxagliptin	I
,	O
sitagliptin	I
,	O
pioglitazone	I
,	O
second-generation	I
sulfonylureas	I
,	O
or	O
long-acting	O
insulin	I
products	O
from	O
2006	O
to	O
2013	O
.	O

MEASUREMENTS	O
:	O

Hospitalized	I
HF	I
,	O
identified	O
by	O
International	O
Classification	O
of	O
Diseases	I
,	O
Ninth	O
Revision	O
,	O
Clinical	I
Modification	O
codes	O
402.x1	O
,	O
404.x1	O
,	O
404.x3	O
,	O
and	O
428.xx	O
recorded	O
as	O
the	O
principal	O
discharge	I
diagnosis	I
.	O

RESULTS	O
:	O

78	O
553	O
saxagliptin	I
users	O
and	O
298	O
124	O
sitagliptin	I
users	O
contributed	O
an	O
average	O
of	O
7	O
to	O
9	O
months	O
of	O
follow-up	I
data	O
to	O
1	O
or	O
more	O
pairwise	O
comparisons	O
.	O

The	O
risk	O
for	O
hHF	O
was	O
not	O
higher	O
with	O
DPP-4	I
inhibitors	I
than	O
with	O
the	O
other	O
study	O
drugs	I
.	O

The	O
hazard	I
ratios	I
from	O
the	O
disease	I
risk	I
score	I
(DRS)-stratified	I
analyses	O
were	O
0.83	O
(	O
95	O
%	O
CI	I
,	O
0.70	O
to	O
0.99	O
)	O
for	O
saxagliptin	I
versus	O
sitagliptin	I
,	O
0.63	O
(	O
CI	I
,	O
0.47	O
to	O
0.85	O
)	O
for	O
saxagliptin	I
versus	O
pioglitazone	I
,	O
0.69	O
(	O
CI	I
,	O
0.54	O
to	O
0.87	O
)	O
for	O
saxagliptin	I
versus	O
sulfonylureas	I
,	O
and	O
0.61	O
(	O
CI	I
,	O
0.50	O
to	O
0.73	O
)	O
for	O
saxagliptin	I
versus	O
insulin	I
.	O

The	O
DRS-stratified	I
hazard	I
ratios	I
were	O
0.74	O
(	O
CI	I
,	O
0.64	O
to	O
0.85	O
)	O
for	O
sitagliptin	I
versus	O
pioglitazone	I
,	O
0.86	O
(	O
CI	I
,	O
0.77	O
to	O
0.95	O
)	O
for	O
sitagliptin	I
versus	O
sulfonylureas	I
,	O
and	O
0.71	O
(	O
CI	I
,	O
0.64	O
to	O
0.78	O
)	O
for	O
sitagliptin	I
versus	O
insulin	I
.	O

Results	O
from	O
the	O
1:1	O
propensity	I
score-matched	I
analyses	O
were	O
similar	O
.	O

Results	O
were	O
also	O
similar	O
in	O
subgroups	O
of	O
patients	I
with	O
and	O
without	O
prior	O
cardiovascular	I
disease	I
and	O
in	O
a	O
subgroup	O
defined	O
by	O
the	O
2	O
highest	O
DRS	I
deciles	O
.	O

LIMITATION	O
:	O

Residual	O
confounding	O
and	O
short	O
follow-up	I
.	O

CONCLUSION	O
:	O

In	O
this	O
large	O
cohort	I
study	I
,	O
a	O
higher	O
risk	O
for	O
hHF	O
was	O
not	O
observed	O
in	O
users	O
of	O
saxagliptin	I
or	O
sitagliptin	I
compared	O
with	O
other	O
selected	O
antihyperglycemic	I
agents	I
.	O

Psychosocial	I
Factors	O
,	O
Exercise	O
Adherence	O
,	O
and	O
Outcomes	I
in	O
Heart	I
Failure	I
Patients	I
:	O
Insights	O
From	O
Heart	I
Failure	I
:	O
A	O
Controlled	O
Trial	O
Investigating	O
Outcomes	I
of	O
Exercise	O
Training	O
(	O
HF-ACTION	I
)	O
.	O

BACKGROUND	O
:	O

Psychosocial	I
factors	O
may	O
influence	O
adherence	O
with	O
exercise	O
training	O
for	O
heart	I
failure	I
(	O
HF	I
)	O
patients	I
.	O

We	O
aimed	O
to	O
describe	O
the	O
association	O
between	O
social	O
support	O
and	O
barriers	O
to	O
participation	O
with	O
exercise	O
adherence	O
and	O
clinical	I
outcomes	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Of	O
patients	I
enrolled	O
in	O
Heart	I
Failure	I
:	O
A	O
Controlled	O
Trial	O
Investigating	O
Outcomes	I
of	O
Exercise	O
Training	O
(	O
HF-ACTION	I
)	O
,	O
2279	O
(	O
97.8	O
%	O
)	O
completed	O
surveys	O
to	O
assess	O
social	O
support	O
and	O
barriers	O
to	O
exercise	O
,	O
resulting	O
in	O
the	O
perceived	O
social	O
support	O
score	O
(	O
PSSS	O
)	O
and	O
barriers	O
to	O
exercise	O
score	O
(	O
BTES	O
)	O
.	O

Higher	O
PSSS	O
indicated	O
higher	O
levels	O
of	O
social	O
support	O
,	O
whereas	O
higher	O
BTES	O
indicated	O
more	O
barriers	O
to	O
exercise	O
.	O

Exercise	O
time	O
at	O
3	O
and	O
12	O
months	O
correlated	I
with	O
PSSS	O
(	O
r	I
=	O
0.09	O
and	O
r	I
=	O
0.13	O
,	O
respectively	O
)	O
and	O
BTES	O
(	O
r=-0.11	I
and	O
r=-0.12	I
,	O
respectively	O
)	O
,	O
with	O
higher	O
exercise	O
time	O
associated	O
with	O
higher	O
PSSS	O
and	O
lower	O
BTES	O
(	O
All	O
P	I
<	O
0.005	O
)	O
.	O

For	O
cardiovascular	I
death	I
or	O
HF	I
hospitalization	I
,	O
there	O
was	O
a	O
significant	I
interaction	O
between	O
the	O
randomization	I
group	O
and	O
BTES	O
(	O
P=0.035	I
)	O
,	O
which	O
corresponded	O
to	O
a	O
borderline	O
association	O
between	O
increasing	O
BTES	O
and	O
cardiovascular	I
death	I
or	O
HF	I
hospitalization	I
in	O
the	O
exercise	O
group	O
(	O
hazard	I
ratio	I
1.25	O
,	O
95	O
%	O
confidence	I
interval	I
0.99	O
,	O
1.59	O
)	O
,	O
but	O
no	O
association	O
in	O
the	O
usual	O
care	O
group	O
(	O
hazard	I
ratio	I
0.83	O
,	O
95	O
%	O
confidence	I
interval	I
0.66	O
,	O
1.06	O
)	O
.	O

CONCLUSIONS	O
:	O

Poor	O
social	O
support	O
and	O
high	O
barriers	O
to	O
exercise	O
were	O
associated	O
with	O
lower	O
exercise	O
time	O
.	O

PSSS	O
did	O
not	O
impact	O
the	O
effect	O
of	O
exercise	O
training	O
on	O
outcomes	I
.	O

However	O
,	O
for	O
cardiovascular	I
death	I
or	O
HF	I
hospitalization	I
,	O
exercise	O
training	O
had	O
a	O
greater	O
impact	O
on	O
patients	I
with	O
lower	O
BTES	O
.	O

Given	O
that	O
exercise	O
training	O
improves	O
outcomes	I
in	O
HF	I
patients	I
,	O
assessment	O
of	O
perceived	O
barriers	O
may	O
facilitate	O
individualized	O
approaches	O
to	O
implement	O
exercise	O
training	O
therapy	I
in	O
clinical	I
practice	O
.	O

Measuring	O
heart	I
failure	I
care	O
by	O
30-day	O
readmission	I
:	O
Rethinking	O
the	O
quality	O
of	O
outcome	I
measures	O
.	O

The	O
Centers	O
for	O
Medicare	O
and	O
Medicaid	O
Services	O
(	O
CMS	O
)	O
has	O
operationalized	O
hospital	I
quality	O
of	O
care	O
outcomes	I
through	O
publicly	O
reported	O
30-day	O
risk-standardized	O
mortality	I
and	O
readmission	I
rates	O
and	O
associated	O
penalties	O
for	O
higher-than-expected	O
rates	O
.	O

The	O
objective	O
of	O
the	O
measure	O
is	O
to	O
motivate	O
hospitals	I
to	O
improve	O
the	O
quality	O
of	O
care	O
they	O
provide	O
patients	I
hospitalized	I
for	O
heart	I
failure	I
(	O
HF	I
)	O
and	O
other	O
conditions	I
such	O
as	O
acute	I
myocardial	I
infarction	I
,	O
pneumonia	I
,	O
with	O
expected	O
future	O
expansion	O
to	O
other	O
conditions	I
.	O

Robot-assisted	O
training	O
for	O
heart	I
failure	I
patients	I
-	O
a	O
small	O
pilot	O
study	O
.	O

OBJECTIVE	O
:	O

The	O
objective	O
of	O
this	O
study	O
was	O
assess	O
robot-assisted	O
gait	O
therapy	I
with	O
the	O
Lokomat®	O
system	O
in	O
heart	I
failure	I
patients	I
.	O

METHODS	O
:	O

Patients	I
(	O
n	O
=	O
5	O
)	O
with	O
stable	I
heart	I
failure	I
and	O
a	O
left	I
ventricular	I
ejection	I
fraction	I
of	O
less	O
than	O
45	O
%	O
completed	O
a	O
four-week	O
aerobic	O
training	O
period	O
with	O
three	O
trainings	O
per	O
week	O
and	O
an	O
integrated	O
dynamic	O
resistance	O
training	O
of	O
the	O
lower	O
limbs	O
.	O

Patients	I
underwent	O
testing	O
of	O
cardiac	I
and	O
inflammatory	I
biomarkers	I
.	O

A	O
cardiopulmonary	I
exercise	I
test	I
,	O
a	O
quality	I
of	I
life	I
score	O
and	O
an	O
evaluation	O
of	O
the	O
muscular	I
strength	O
by	O
measuring	O
the	O
peak	I
quadriceps	I
force	I
was	O
performed	O
.	O

RESULTS	O
:	O

No	O
adverse	I
events	I
occurred	O
.	O

The	O
combined	O
training	O
resulted	O
in	O
an	O
improvement	O
in	O
peak	I
work	I
rate	I
(	O
range	O
:	O
6	O
%	O
to	O
36	O
%	O
)	O
and	O
peak	I
quadriceps	I
force	I
(	O
range	O
:	O
3	O
%	O
to	O
80	O
%	O
)	O
in	O
all	O
participants	O
.	O

Peak	I
oxygen	I
consumption	I
(	O
range	O
:	O
–3	O
%	O
to	O
+	O
61	O
%	O
)	O
increased	O
in	O
three	O
,	O
and	O
oxygen	O
pulse	I
(	O
range	O
:	O
–7	O
%	O
to	O
+	O
44	O
%	O
)	O
in	O
four	O
of	O
five	O
patients	I
.	O

The	O
quality	I
of	I
life	I
assessment	O
indicated	O
better	O
well-being	O
in	O
all	O
participants	O
.	O

NT-ProBNP	I
(	O
+	O
233	O
to	O
–733	O
ng	O
/	O
ml	O
)	O
and	O
the	O
inflammatory	I
biomarkers	I
(	O
hsCRP	I
and	O
IL6	I
)	O
decreased	O
in	O
four	O
of	O
five	O
patients	I
(	O
IL	O
6	O
:	O
+	O
0.5	O
to	O
–2	O
mg	O
/	O
l	O
,	O
hsCRP	I
:	O
+	O
0.2	O
to	O
–6.5	O
mg	O
/	O
l	O
)	O
.	O

CONCLUSIONS	O
:	O

Robot-assisted	O
gait	O
therapy	I
with	O
the	O
Lokomat®	O
System	O
is	O
feasible	O
in	O
heart	I
failure	I
patients	I
and	O
was	O
safe	O
in	O
this	O
trial	O
.	O

The	O
combined	O
aerobic	O
and	O
resistance	O
training	O
intervention	O
with	O
augmented	O
feedback	O
resulted	O
in	O
benefits	O
in	O
exercise	I
capacity	I
,	O
muscle	I
strength	O
and	O
quality	I
of	I
life	I
,	O
as	O
well	O
as	O
an	O
improvement	O
of	O
cardiac	I
(	O
NT-ProBNP	I
)	O
and	O
inflammatory	I
(	O
IL6	I
,	O
hsCRP	I
)	O
biomarkers	I
.	O

Results	O
can	O
only	O
be	O
considered	O
as	O
preliminary	O
and	O
need	O
further	O
validation	O
in	O
larger	O
studies	O
.	O

Effectiveness	O
and	O
safety	O
of	O
spironolactone	I
for	O
systolic	I
heart	I
failure	I
.	O

Aldosterone	I
receptor	I
antagonists	I
have	O
been	O
shown	O
in	O
randomized	I
trials	O
to	O
reduce	O
morbidity	I
and	O
mortality	I
in	O
adults	O
with	O
symptomatic	I
systolic	I
heart	I
failure	I
.	O

We	O
studied	O
the	O
effectiveness	O
and	O
safety	O
of	O
spironolactone	I
in	O
adults	O
with	O
newly	O
diagnosed	I
systolic	I
heart	I
failure	I
in	O
clinical	I
practice	O
.	O

We	O
identified	O
all	O
adults	O
with	O
newly	O
diagnosed	I
heart	I
failure	I
,	O
left	I
ventricular	I
ejection	I
fraction	I
of	O
<	O
40	O
%	O
,	O
and	O
no	O
previous	O
spironolactone	I
use	O
from	O
2006	O
to	O
2008	O
in	O
Kaiser	O
Permanente	O
Northern	O
California	O
.	O

We	O
excluded	O
patients	I
with	O
baseline	I
serum	I
creatinine	I
level	O
of	O
>	O
2.5	O
mg	O
/	O
dl	O
or	O
a	O
serum	I
potassium	I
level	O
of	O
>	O
5.0	O
mEq	O
/	O
L.	O
We	O
used	O
Cox	I
regression	I
with	O
time-varying	O
covariates	I
to	O
evaluate	O
the	O
independent	O
association	O
between	O
spironolactone	I
use	O
and	O
death	I
,	O
hospitalization	I
,	O
severe	O
hyperkalemia	I
,	O
and	O
acute	I
kidney	I
injury	I
.	O

Among	O
2,538	O
eligible	O
patients	I
with	O
a	O
median	O
follow-up	I
of	O
2.5	O
years	O
,	O
521	O
patients	I
(	O
22	O
%	O
)	O
initiated	O
spironolactone	I
,	O
which	O
was	O
not	O
associated	O
with	O
risk	O
of	O
hospitalization	I
(	O
adjusted	O
hazard	I
ratio	I
0.91	O
,	O
95	O
%	O
confidence	I
interval	I
0.77	O
to	O
1.08	O
)	O
or	O
death	I
(	O
adjusted	O
hazard	I
ratio	I
0.93	O
,	O
confidence	I
interval	I
0.60	O
to	O
1.44	O
)	O
.	O

Crude	O
rates	O
of	O
severe	O
hyperkalemia	I
and	O
acute	I
kidney	I
injury	I
during	O
spironolactone	I
use	O
were	O
similar	O
to	O
that	O
seen	O
in	O
clinical	I
trials	O
.	O

Spironolactone	I
was	O
independently	O
associated	O
with	O
a	O
3.5-fold	O
increased	O
risk	O
of	O
hyperkalemia	I
but	O
not	O
with	O
acute	I
kidney	I
injury	I
.	O

Within	O
a	O
diverse	O
community-based	O
cohort	O
with	O
incident	O
systolic	I
heart	I
failure	I
,	O
use	O
of	O
spironolactone	I
was	O
not	O
independently	O
associated	O
with	O
risks	O
of	O
hospitalization	I
or	O
death	I
.	O

Our	O
findings	O
suggest	O
that	O
the	O
benefits	O
of	O
spironolactone	I
in	O
clinical	I
practice	O
may	O
be	O
reduced	O
compared	O
with	O
other	O
guideline-recommended	O
medications	I
.	O

Race	O
influences	O
the	O
safety	O
and	O
efficacy	O
of	O
spironolactone	I
in	O
severe	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

The	O
incidence	I
of	O
hyperkalemia	I
caused	O
by	O
mineralocorticoid	I
receptor	I
antagonists	I
may	O
vary	O
by	O
race	O
,	O
but	O
whether	O
race	O
influences	O
efficacy	O
of	O
mineralocorticoid	I
receptor	I
antagonists	I
in	O
heart	I
failure	I
(	O
HF	I
)	O
is	O
unknown	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
assessed	O
hyperkalemia	I
and	O
outcomes	I
in	O
African	O
Americans	O
(	O
AAs	O
;	O
n=120	O
)	O
and	O
non-AAs	O
(	O
n=1543	O
;	O
white	O
93	O
%	O
)	O
with	O
New	O
York	O
Heart	I
Association	O
(	O
NYHA	I
)	I
class	I
III	I
or	O
IV	I
HF	I
and	O
left	I
ventricular	I
dysfunction	I
who	O
were	O
randomized	I
to	O
spironolactone	I
,	O
titrated	I
to	O
25	O
or	O
50	O
mg	O
daily	O
or	O
placebo	I
,	O
in	O
the	O
Randomized	I
Aldactone	I
Evaluation	O
Study	O
(	O
RALES	O
)	O
.	O

AA	O
participants	O
were	O
significantly	I
younger	O
,	O
less	O
likely	O
to	O
have	O
an	O
ischemic	I
HF	I
pathogenesis	I
,	O
more	O
likely	O
to	O
be	O
NYHA	I
functional	I
class	I
IV	I
,	O
and	O
more	O
likely	O
to	O
have	O
a	O
higher	O
estimated	I
glomerular	I
filtration	I
rate	I
and	O
heart	I
rate	I
,	O
less	O
hypertension	I
,	O
diabetes	I
mellitus	I
,	O
or	O
history	O
of	O
myocardial	I
infarction	I
compared	O
with	O
non-AA	O
participants	O
.	O

Potassium	I
increased	O
with	O
spironolactone	I
in	O
non-AAs	O
(	O
4.29±0.5-4.55±0.49	O
mmol	O
/	O
L	O
)	O
but	O
not	O
in	O
AAs	O
(	O
4.32±0.54-4.31±0.49	O
mmol	O
/	O
L	O
;	O
race	O
by	O
treatment	O
interaction	O
,	O
P=0.03	I
)	O
during	O
the	O
first	O
month	O
and	O
remained	O
higher	O
throughout	O
the	O
trial	O
.	O

Compared	O
with	O
AAs	O
,	O
non-AAs	O
were	O
more	O
likely	O
to	O
attain	O
maximal	O
spironolactone	I
dose	O
(	O
13.9	O
%	O
versus	O
5.8	O
%	O
;	O
P=0.04	I
)	O
and	O
had	O
higher	O
rates	O
of	O
hyperkalemia	I
(	O
potassium	I
>	O
5.5	O
mmol	O
/	O
L	O
;	O
9.7	O
%	O
versus	O
4.2	O
%	O
;	O
P	I
<	O
0.046	O
)	O
,	O
as	O
well	O
as	O
lower	O
rates	O
of	O
hypokalemia	I
(	O
potassium	I
<	O
3.5	O
mmol	O
/	O
L	O
;	O
5.6	O
%	O
versus	O
17.9	O
%	O
;	O
P	I
<	O
0.001	O
)	O
.	O

After	O
adjustment	O
for	O
differences	O
in	O
baseline	I
characteristics	O
and	O
achieved	O
study	O
drug	I
dose	O
,	O
spironolactone	I
reduced	O
the	O
combined	I
end	I
point	I
of	O
death	I
or	O
hospitalization	I
for	O
HF	I
in	O
non-AAs	O
(	O
hazard	I
ratio	I
,	O
0.63	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.55	O
-	O
0.73	O
)	O
but	O
not	O
in	O
AAs	O
(	O
hazard	I
ratio	I
,	O
1.07	O
;	O
95	O
%	O
confidence	I
interval	I
,	O
0.67	O
-	O
1.71	O
;	O
P	I
value	I
for	O
interaction=0.032	O
)	O
.	O

CONCLUSIONS	O
:	O

AAs	O
with	O
HF	I
exhibited	O
less	O
hyperkalemia	I
and	O
more	O
hypokalemia	I
with	O
spironolactone	I
compared	O
with	O
non-AAs	O
and	O
seemed	O
to	O
derive	O
less	O
clinical	I
benefit	O
.	O

These	O
hypothesis-generating	O
findings	O
suggest	O
that	O
safety	O
and	O
efficacy	O
of	O
mineralocorticoid	I
receptor	I
antagonists	I
may	O
differ	O
by	O
race	O
.	O

Cardiology	I
:	O
Bromodomain	I
inhibition	O
halts	O
heart	I
failure	I
.	O

Heart	I
failure	I
(	O
HF	I
)	O
is	O
the	O
leading	O
cause	O
of	O
mortality	I
in	O
modern	O
society	O
.	O

It	O
is	O
a	O
consequence	O
of	O
pathological	I
remodelling	I
of	O
the	O
heart	I
,	O
which	O
involves	O
cardiac	I
hypertrophy	I
(	O
a	O
robust	O
predictor	O
of	O
subsequent	O
HF	I
and	O
death	I
)	O
,	O
fibrosis	I
and	O
inflammation	I
.	O

At	O
the	O
molecular	O
level	O
,	O
HF	I
has	O
been	O
associated	O
with	O
chromatin	I
hyperacetylation	I
.	O

Now	O
,	O
reporting	O
in	O
Cell	O
,	O
Anand	O
et	O
al.	O
show	O
that	O
the	O
BET	I
family	O
bromodomain	I
proteins	I
(	O
BETs	I
)	O
,	O
a	O
family	O
of	O
acetyl-lysine	I
reader	I
proteins	I
,	O
are	O
central	O
to	O
HF	I
pathogenesis	I
and	O
that	O
they	O
are	O
promising	O
targets	O
for	O
the	O
prevention	O
of	O
HF	I
.	O

The	O
remodelling	I
that	O
precedes	O
HF	I
is	O
induced	O
by	O
haemodynamic	I
and	O
neuronal	I
stressors	I
.	O

These	O
activate	O
a	O
signal	I
transduction	I
cascade	O
that	O
converges	O
on	O
a	O
defined	O
set	O
of	O
transcription	I
factors	I
,	O
and	O
pathological	I
changes	O
in	O
cardiomyocytes	I
occur	O
through	O
an	O
interplay	O
between	O
these	O
transcription	I
factors	I
and	O
epigenetic	I
changes	O
in	O
chromatin	I
structure	I
.	O

Both	O
epigenetic	I
'	I
writer	I
'	O
proteins	I
(	O
histone	I
acetyltransferases	I
)	O
and	O
epigenetic	I
'	O
erasers	I
'	O
(	O
histone	I
deacetylases	I
)	O
have	O
been	O
implicated	O
in	O
cardiac	I
development	O
and	O
disease	I
.	O

However	O
,	O
the	O
role	O
of	O
'	O
readers	O
'	O
(	O
bromodomain	I
proteins	I
)	O
was	O
less	O
well	O
defined	O
.	O

The	O
group	O
utilized	O
the	O
recently	O
developed	O
first-in-class	O
inhibitor	O
JQ1	I
,	O
which	O
displaces	O
BETs	I
from	O
chromatin	I
,	O
resulting	O
in	O
the	O
suppression	O
of	O
downstream	I
signalling	I
to	O
RNA	I
polymerase	I
II	I
(	O
Pol	I
II	I
)	O
.	O

Investigating	O
the	O
role	O
of	O
BETs	I
in	O
an	O
in	I
vitro	I
model	O
of	O
neurohormonally	I
induced	O
heart	I
disease	I
,	O
the	O
authors	O
showed	O
that	O
nanomolar	I
doses	O
of	O
JQ1	I
significantly	I
blocked	O
phenylephrine-mediated	I
hypertrophy	I
of	O
cardiomyocytes	I
and	O
pathological	I
gene	I
induction	I
.	O

Similar	O
results	O
were	O
achieved	O
through	O
knockdown	O
of	O
the	O
BET	I
bromodomain-containing	I
protein	I
4	I
(	O
BRD4	I
)	O
,	O
which	O
is	O
highly	O
expressed	O
in	O
cardiac	I
tissues	O
.	O

Gene	I
expression	I
profiling	O
of	O
cultured	O
cardiomyocytes	I
in	O
the	O
presence	O
or	O
absence	O
of	O
JQ1	I
showed	O
that	O
the	O
drug	I
abrogated	O
the	O
induction	O
of	O
a	O
substantial	O
subset	O
of	O
phenylephrine-induced	I
genes	I
.	O

In	I
vivo	I
experiments	O
of	O
HF	I
induced	O
in	O
mice	O
via	O
phenylephrine	I
or	O
haemodynamic	I
stress	O
(	O
using	O
the	O
surgical	I
method	O
of	O
transverse	I
aortic	I
constriction	I
(	O
TAC	I
)	O
)	O
showed	O
that	O
JQ1	I
protected	O
against	O
several	O
pathological	I
changes	O
,	O
including	O
cardiac	I
hypertrophy	I
.	O

Importantly	O
,	O
no	O
toxicity	O
or	O
effects	O
on	O
systemic	I
blood	I
pressure	I
were	O
observed	O
.	O

Detailed	O
transcriptional	O
analysis	O
of	O
cardiac	I
tissue	O
from	O
mice	O
that	O
were	O
either	O
TAC	I
-	O
or	O
sham-operated	O
and	O
treated	O
with	O
either	O
JQ1	I
or	O
vehicle	O
revealed	O
that	O
BET	I
inhibition	O
suppresses	O
a	O
pathological	I
cardiac	I
gene	I
expression	I
programme	O
.	O

Importantly	O
,	O
the	O
targets	O
of	O
BETs	I
in	O
the	O
mouse	O
TAC	I
model	O
were	O
also	O
found	O
to	O
be	O
relevant	O
in	O
human	O
HF	I
.	O

Further	O
molecular	O
analysis	O
revealed	O
that	O
BETs	I
play	O
a	O
crucial	O
role	O
in	O
chromatin-mediated	I
signal	I
transduction	I
to	O
Pol	I
II	I
,	O
co-activating	O
transcription	I
factor	I
networks	O
that	O
are	O
known	O
to	O
be	O
causal	O
in	O
HF	I
pathogenesis	I
,	O
including	O
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	I
)	O
,	O
nuclear	I
factor-κB	I
(	O
NF-κB	I
)	O
and	O
the	O
transcription	I
factor	I
GATA4	I
.	O

Moreover	O
,	O
BETs	I
were	O
found	O
to	O
function	O
,	O
in	O
part	O
,	O
by	O
promoting	O
transcriptional	I
pause	I
release	I
(	O
and	O
thereby	O
re-activating	O
transcription	O
)	O
during	O
pathological	I
stress	O
.	O

This	O
study	O
implicates	O
epigenetic	I
readers	O
in	O
cardiac	I
biology	O
and	O
suggests	O
that	O
the	O
manipulation	O
of	O
cardiac	I
gene	I
control	O
via	O
the	O
targeting	O
of	O
chromatin-dependent	I
signal	I
transduction	I
could	O
potentially	O
abrogate	O
pathological	I
gene	I
expression	I
and	O
HF	I
progression	O
.	O

Comment	O
on	O
Baroreflex	I
Activation	I
Therapy	I
for	O
the	O
Treatment	O
of	O
Heart	I
Failure	I
With	I
a	I
Reduced	I
Ejection	I
Fraction	I

OBJECTIVES	O
:	O

The	O
objective	O
of	O
this	O
clinical	I
trial	O
was	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
carotid	I
baroreflex	I
activation	I
therapy	I
(	O
BAT	I
)	O
in	O
advanced	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

BACKGROUND	O
:	O

Increased	O
sympathetic	I
and	O
decreased	O
parasympathetic	I
activity	I
contribute	O
to	O
HF	I
symptoms	I
and	O
disease	I
progression	O
.	O

BAT	I
results	O
in	O
centrally	O
mediated	O
reduction	O
of	O
sympathetic	I
outflow	I
and	O
increased	O
parasympathetic	I
activity	I
.	O

METHODS	O
:	O

Patients	I
with	O
New	O
York	O
Heart	I
Association	O
(	O
NYHA	O
)	O
functional	I
class	I
III	I
HF	I
and	O
ejection	I
fractions	I
<	O
35	O
%	O
on	O
chronic	I
stable	I
guideline-directed	I
medical	I
therapy	I
(	O
GDMT	I
)	O
were	O
enrolled	O
at	O
45	O
centers	O
in	O
the	O
United	O
States	O
,	O
Canada	O
,	O
and	O
Europe	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
receive	O
ongoing	O
GDMT	I
alone	O
(	O
control	O
group	O
)	O
or	O
ongoing	O
GDMT	I
plus	O
BAT	I
(	O
treatment	O
group	O
)	O
for	O
6	O
months	O
.	O

The	O
primary	O
safety	O
end	I
point	I
was	O
system	O
-	O
and	O
procedure-related	O
major	O
adverse	O
neurological	I
and	O
cardiovascular	I
events	I
.	O

The	O
primary	O
efficacy	O
end	I
points	I
were	O
changes	O
in	O
NYHA	I
functional	I
class	I
,	O
quality-of-life	I
score	O
,	O
and	O
6-minute	I
hall	I
walk	I
distance	O
.	O

RESULTS	O
:	O

One	O
hundred	O
forty-six	O
patients	I
were	O
randomized	I
,	O
70	O
to	O
control	O
and	O
76	O
to	O
treatment	O
.	O

The	O
major	O
adverse	O
neurological	I
and	O
cardiovascular	I
event-free	I
rate	O
was	O
97.2	O
%	O
(	O
lower	O
95	O
%	O
confidence	O
bound	O
91.4	O
%	O
)	O
.	O

Patients	I
assigned	O
to	O
BAT	I
,	O
compared	O
with	O
control	O
group	O
patients	I
,	O
experienced	O
improvements	O
in	O
the	O
distance	O
walked	O
in	O
6	O
min	O
(	O
59.6	O
±	O
14	O
m	O
vs.	O
1.5	O
±	O
13.2	O
m	O
;	O
p	I
=	O
0.004	O
)	O
,	O
quality-of-life	I
score	O
(	O
–17.4	O
±	O
2.8	O
points	O
vs.	O
2.1	O
±	O
3.1	O
points	O
;	O
p	I
<	O
0.001	O
)	O
,	O
and	O
NYHA	I
functional	I
class	I
ranking	O
(	O
p	I
=	O
0.002	O
for	O
change	O
in	O
distribution	O
)	O
.	O

BAT	I
significantly	I
reduced	O
N-terminal	I
pro-brain	I
natriuretic	I
peptide	I
(	O
p	I
=	O
0.02	O
)	O
and	O
was	O
associated	O
with	O
a	O
trend	O
toward	O
fewer	O
days	O
hospitalized	I
for	O
HF	I
(	O
p	I
=	O
0.08	O
)	O
.	O

CONCLUSIONS	O
:	O

BAT	I
is	O
safe	O
and	O
improves	O
functional	I
status	I
,	O
quality	I
of	I
life	I
,	O
exercise	I
capacity	I
,	O
N-terminal	I
pro-brain	I
natriuretic	I
peptide	I
,	O
and	O
possibly	O
the	O
burden	O
of	O
heart	I
failure	I
hospitalizations	I
in	O
patients	I
with	O
GDMT-treated	I
NYHA	I
functional	I
class	I
III	I
HF	I
.	O

Vascular	I
endothelial	I
growth	I
factor	I
blockade	I
prevents	O
the	O
beneficial	O
effects	O
of	O
beta-blocker	I
therapy	I
on	O
cardiac	I
function	I
,	O
angiogenesis	I
,	O
and	O
remodeling	I
in	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Impaired	O
angiogenesis	I
in	O
the	O
post-myocardial	I
infarction	I
heart	I
contributes	O
to	O
the	O
progression	O
to	O
heart	I
failure	I
.	O

The	O
inhibition	O
of	O
vascular	I
endothelial	I
growth	I
factor	I
(	O
VEGF	I
)	O
signaling	I
has	O
been	O
shown	O
to	O
be	O
crucial	O
for	O
the	O
transition	O
from	O
compensatory	I
hypertrophy	I
to	O
cardiac	I
failure	I
.	O

Importantly	O
,	O
β-adrenergic	I
receptor	I
blocker	I
therapy	I
has	O
been	O
also	O
shown	O
to	O
improve	O
myocardial	I
perfusion	I
by	O
enhancing	O
neoangiogenesis	I
in	O
the	O
failing	O
heart	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Eight	O
weeks	O
from	O
surgically	I
induced	O
myocardial	I
infarction	I
,	O
heart	I
failure	I
rats	O
were	O
randomized	I
to	O
receive	O
bisoprolol	I
(	O
B	O
)	O
or	O
vehicle	O
.	O

At	O
the	O
end	O
of	O
a	O
10-week	O
treatment	O
period	O
,	O
echocardiography	I
revealed	O
reduced	O
cardiac	I
diameters	O
and	O
improved	O
cardiac	I
function	I
in	O
B-treated	O
compared	O
with	O
vehicle-treated	O
rats	O
.	O

Moreover	O
,	O
B	O
treatment	O
was	O
associated	O
with	O
increased	O
cardiac	I
angiogenesis	I
and	O
in	I
vivo	I
coronary	I
perfusion	I
and	O
reduced	O
cardiac	I
fibrosis	I
.	O

Importantly	O
,	O
2	O
weeks	O
after	O
B	O
treatment	O
was	O
started	O
,	O
increased	O
cardiac	I
VEGF	I
expression	I
and	O
Akt	I
and	O
endothelial	I
NO	I
synthase	I
activation	I
were	O
observed	O
by	O
comparing	O
B-treated	O
with	O
drug-untreated	I
failing	O
hearts	I
.	O

To	O
test	O
whether	O
the	O
proangiogenic	I
effects	O
of	O
B	O
act	O
via	O
activation	O
of	O
VEGF	I
pathway	I
,	O
rats	O
were	O
intravenously	I
injected	I
with	O
adenoviral	I
vector	O
encoding	O
a	O
decoy	O
VEGF	I
receptor	I
(	O
Ad-Flk	O
)	O
or	O
a	O
control	O
adenovirus	I
(	O
Ad-C	O
)	O
,	O
at	O
the	O
start	O
of	O
the	O
treatment	O
with	O
B.	O
After	O
10	O
weeks	O
,	O
histological	I
analysis	O
revealed	O
reduced	O
capillary	I
and	O
coronary	I
perfusion	I
in	O
B-treated	O
plus	O
Ad-Flk	O
rats	O
compared	O
with	O
B-treated	O
plus	O
Ad-C	O
rats	O
.	O

Moreover	O
,	O
VEGF	I
inhibition	I
counteracted	O
the	O
positive	O
effects	O
of	O
B	O
on	O
cardiac	I
function	I
and	O
remodeling	I
.	O

CONCLUSIONS	O
:	O

β-Blockade	I
promotes	O
cardiac	I
angiogenesis	I
in	O
heart	I
failure	I
via	O
activation	O
of	O
VEGF	I
signaling	I
pathway	I
.	O

β-Blocker-induced	I
enhancement	O
of	O
cardiac	I
angiogenesis	I
is	O
essential	O
for	O
the	O
favorable	O
effects	O
of	O
this	O
therapy	I
on	O
cardiac	I
function	I
and	O
remodeling	I
.	O

Cross-talk	I
between	O
the	O
heart	I
and	O
adipose	I
tissue	I
in	O
cachectic	I
heart	I
failure	I
patients	I
with	O
respect	O
to	O
alterations	O
in	O
body	O
composition	O
:	O
a	O
prospective	I
study	I
.	O

OBJECTIVES	O
:	O

Cardiac	I
cachexia	I
(	O
CC	I
)	O
is	O
associated	O
with	O
changes	O
in	O
body	O
composition	O
.	O

Lipolysis	I
and	O
increased	O
energy	O
expenditure	O
caused	O
by	O
A	I
-	I
and	O
B	I
natriuretic	I
peptides	I
(	O
NPs	I
)	O
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
CC	I
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
neurohormones	I
and	O
adipokines	I
are	O
associated	O
with	O
body	O
composition	O
in	O
CC	I
and	O
that	O
a	O
progressive	O
loss	O
of	O
fat	I
free	I
mass	I
(	O
FFM	I
)	O
and	O
fat	I
mass	I
(	O
FM	I
)	O
takes	O
place	O
.	O

METHODS	O
:	O

Body	O
composition	O
with	O
regard	O
to	O
FFM	I
,	O
FM	I
,	O
and	O
body	O
fat	O
distribution	O
was	O
assessed	O
by	O
dual	I
energy	I
X-ray	I
absorptiometry	I
(	O
DXA	I
)	O
in	O
19	O
non-diabetic	I
patients	I
with	O
chronic	I
heart	I
failure	I
(	O
CHF	I
)	O
and	O
CC	I
and	O
38	O
controls	O
(	O
non-cachectic	I
CHF	I
and	O
individuals	O
with	O
prior	O
myocardial	I
infarction-both	I
n	O
=	O
19	O
)	O
who	O
were	O
followed	O
for	O
12	O
months	O
.	O

Biomarkers	I
of	O
neurohormonal	I
stimulation	I
,	O
inflammation	I
,	O
and	O
endothelial	I
dysfunction	I
were	O
measured	O
.	O

RESULTS	O
:	O

N-terminal	I
proBNP	I
(	O
NT-proBNP	I
)	O
,	O
midregional	I
proANP	I
(	O
MR-proANP	I
)	O
,	O
and	O
total	O
adiponectin	I
were	O
elevated	O
in	O
CHF	I
(	O
p	I
<	O
0.001	O
)	O
and	O
correlated	I
inversely	O
to	O
BMI	I
and	O
FM	I
.	O

An	O
inverse	I
correlation	I
was	O
observed	O
between	O
pro-adrenomedullin	I
(	O
MR-proADM	I
)	O
and	O
FFM	I
.	O

During	O
follow	I
up	I
body	O
weight	O
was	O
unaltered	O
in	O
all	O
groups	O
even	O
though	O
FM	I
increased	O
by	O
1.35	O
kg	O
(	O
p	I
<	O
0.05	O
)	O
and	O
FFM	I
decreased	O
by	O
0.5	O
kg	O
(	O
p	I
<	O
0.05	O
)	O
in	O
CC	I
patients	I
.	O

The	O
latter	O
correlated	I
inversely	O
to	O
baseline	I
NT-proBNP	I
,	O
MR-proANP	I
,	O
and	O
MR-proADM	I
(	O
p	I
<	O
0.05	O
)	O
.	O

No	O
correlation	I
to	O
changes	O
in	O
FM	I
was	O
found	O
.	O

CONCLUSIONS	O
:	O

FM	I
was	O
associated	O
with	O
plasma	I
NPs	I
and	O
total	O
adiponectin	I
at	O
baseline	I
;	O
whereas	O
changes	O
in	O
FM	I
and	O
FFM	I
did	O
not	O
correlate	I
to	O
changes	O
in	O
NPs	I
or	O
adiponectin	I
during	O
follow	I
up	I
.	O

Prospectively	I
,	O
FFM	I
decreased	O
but	O
FM	I
increased	O
,	O
despite	O
stable	O
body	O
weight	O
in	O
CC	I
.	O

Global	I
left	I
ventricular	I
longitudinal	I
systolic	I
strain	I
as	O
a	O
major	O
predictor	O
of	O
cardiovascular	I
events	I
in	O
patients	I
with	O
atrial	I
fibrillation	I
.	O

OBJECTIVE	O
:	O

Although	O
global	I
left	I
ventricular	I
longitudinal	I
systolic	I
strain	I
(	O
GLS	I
)	O
is	O
a	O
sensitive	O
measure	O
of	O
left	I
ventricular	I
mechanics	O
,	O
its	O
relationship	O
with	O
adverse	O
cardiovascular	I
(	O
CV	I
)	O
events	I
in	O
atrial	I
fibrillation	I
(	O
AF	I
)	O
has	O
not	O
been	O
evaluated	O
.	O

This	O
study	O
sought	O
to	O
examine	O
the	O
ability	O
of	O
GLS	I
in	O
predicting	O
CV	I
events	O
in	O
AF	I
.	O

DESIGN	O
:	O

Observational	I
cohort	I
study	I
.	O

SETTING	O
:	O

Department	O
of	O
cardiology	I
in	O
a	O
university	O
hospital	I
.	O

PATIENTS	I
:	O

196	O
persistent	O
AF	I
patients	I
referred	O
for	O
echocardiographic	I
examination	O
.	O

MAIN	O
OUTCOME	I
MEASURES	O
:	O

The	O
risk	O
of	O
GLS	I
measured	O
by	O
index	O
beat	O
method	O
for	O
CV	I
events	O
was	O
assessed	O
by	O
Cox	I
proportional	I
hazards	I
analyses	I
.	O

CV	I
events	O
were	O
defined	O
as	O
CV	I
death	I
,	O
non-fatal	O
stroke	I
and	O
hospitalisation	I
for	O
heart	I
failure	I
.	O

RESULTS	O
:	O

There	O
were	O
19	O
CV	I
deaths	I
,	O
12	O
non-fatal	O
stroke	I
and	O
28	O
hospitalisations	I
for	O
heart	I
failure	I
during	O
an	O
average	O
follow-up	I
of	O
21	O
±	O
10	O
months	O
.	O

Multivariate	I
analysis	I
showed	O
worsening	O
GLS	I
(	O
HR	I
1.121	O
;	O
95	O
%	O
CI	I
1.023	O
to	O
1.228	O
,	O
p=0.014	I
)	O
was	O
independently	O
associated	O
with	O
increased	O
CV	I
events	O
.	O

In	O
direct	O
comparison	O
,	O
GLS	I
outperformed	O
left	I
ventricular	I
ejection	I
fraction	I
(	O
LVEF	I
)	O
and	O
systolic	I
mitral	I
annulus	I
velocity	I
(	O
Sa	I
)	O
in	O
predicting	O
adverse	O
CV	I
events	O
both	O
in	O
univariate	I
and	O
multivariate	I
models	I
(	O
p	I
≤	O
0.043	O
)	O
.	O

Besides	O
,	O
the	O
addition	O
of	O
GLS	I
to	O
a	O
Cox	I
model	I
containing	O
chronic	I
heart	I
failure	I
,	O
hypertension	I
,	O
age	O
≥	O
75	O
years	O
,	O
diabetes	I
,	O
prior	O
stroke	I
score	O
,	O
estimated	I
glomerular	I
filtration	I
rate	I
,	O
LVEF	I
and	O
Sa	I
provided	O
an	O
additional	O
benefit	O
in	O
the	O
prediction	O
of	O
adverse	O
CV	I
events	O
(	O
p=0.022	I
)	O
.	O

CONCLUSIONS	O
:	O

GLS	I
was	O
a	O
major	O
parameter	O
and	O
stronger	O
than	O
LVEF	I
and	O
Sa	I
in	O
predicting	O
adverse	O
CV	I
events	O
and	O
could	O
offer	O
an	O
additional	O
prognostic	I
benefit	O
over	O
conventional	O
clinical	I
and	O
echocardiographic	I
systolic	I
parameters	O
in	O
AF	I
.	O

